The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin, Nathan Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L Carpenter, Robert Iannone, Stan B Kaye Show all
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2013
This trial was funded by Merck Sharp and Dohme, a subsidiary of Merck. SKS was awarded the 2010 ASCO Annual Meeting Merit Award by the ASCO Conquer Cancer Foundation for presentation of parts of this work. SM was funded by the Prostate Cancer Foundation. The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support to the Institute of Cancer Research was also provided by the Experimental Cancer Medicine Centre. We also acknowledge support from Prostate Cancer UK.